In 2023, Japan's per capita spending on blood and blood-forming organs medicines stood at approximately $46.5. From 2024 to 2028, the per capita expenditure is projected to rise from $47.3 to $50.5, reflecting a steady growth trend. The year-on-year growth rates suggest a consistent increase of 1.7% for each subsequent year within this period. This results in a compound annual growth rate (CAGR) of roughly 1.7% over five years (2023-2028), signaling a stable and positive expansion in this sector.
Future trends to watch for in the Japanese market include an increased focus on innovative therapies and technological advancements in blood-related treatments. Additionally, demographic shifts, such as an aging population, remain critical factors influencing demand in the sector. Monitoring healthcare policies and pricing interventions by the Japanese government will also be essential for anticipating changes in the market dynamics.
